Immune Spatial Features of Guselkumab Cutaneous Response
Part of paid clinical trials in San Francisco, California.
- Sponsor
- University of California, San Francisco
- Study ID
- NCT05858632
- Phase
- PHASE4
- Status
- Recruiting
Conditions
- Psoriasis of Scalp
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Accepted
Interventions
- Guselkumab — DRUGGuselkumab treatment for \~ 9 months
Study Details
This study examines the effect of IL-23 blockade with Guselkumab on the immune cells of scalp psoriasis lesions.
Key Dates
- Start date
- Jul 1, 2023
- Status verified
- Jun 2026
- Primary completion
- Jun 30, 2028
- Completion
- Jun 30, 2028
Study Design
- Enrollment
- 10 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- BASIC_SCIENCE
Arms
- Experimental: Guselkumab treatmentGuselkumab treatment for \~ 9 months
Primary Outcome Measure
Change in psoriasis scalp severity index score (PSSI) [ Time Frame: baseline and 9 months ]
Central Contacts
- Jeffrey Cheng, MD, PhD415 575 0524
- Raymond Cho, MD,PhD
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of California San Francisco | San Francisco | California | 94115 |
Find similar trials in San Francisco, CA
By research site